TipRanks
Clover Biopharmaceuticals Ltd. (HK:2197)
:2197
Hong Kong Market
2197
Clover Biopharmaceuticals Ltd.
RESEARCH TOOLSreports
Want to see HK:2197 full AI Analyst Report?

Clover Biopharmaceuticals Ltd. (2197) Ratios

1 Followers

Clover Biopharmaceuticals Ltd. Ratios

HK:2197's free cash flow for Q2 2026 was ¥-64.46. For the 2026 fiscal year, HK:2197's free cash flow was decreased by ¥ and operating cash flow was ¥-794.55. See a summary of the company’s cash flow.
Ratios
TTM
Dec 25Dec 24Dec 23Dec 22
Liquidity Ratios
Current Ratio
 0.73 0.19 0.35 0.83 1.55
Quick Ratio
 0.71 0.19 0.34 0.53 0.71
Cash Ratio
 0.50 0.16 0.21 0.32 0.57
Solvency Ratio
 0.84 -0.08 -0.35 -0.02 -0.45
Operating Cash Flow Ratio
 -1.45 -0.11 -0.15 -0.32 -0.60
Short-Term Operating Cash Flow Coverage
 0.00 -17.94 -3.90 -2.36 -5.75
Net Current Asset Value
¥ -911.68M¥ -1.92B¥ -1.79B¥ -934.75M¥ -972.91M
Leverage Ratios
Debt-to-Assets Ratio
 <0.01 0.02 0.11 0.16 0.08
Debt-to-Equity Ratio
 >-0.01 >-0.01 -0.05 -0.46 -0.53
Debt-to-Capital Ratio
 >-0.01 >-0.01 -0.06 -0.84 -1.13
Long-Term Debt-to-Capital Ratio
 0.00 0.00 0.00 0.00 0.00
Financial Leverage Ratio
 -0.30 -0.25 -0.50 -2.87 -7.03
Debt Service Coverage Ratio
 -1.26K -20.14 -11.50 -0.14 -7.90
Interest Coverage Ratio
 -1.41K -674.64 -165.25 -137.62 -396.49
Debt to Market Cap
 0.00 <0.01 0.26 0.46 0.12
Interest Debt Per Share
 <0.01 <0.01 0.08 0.28 0.33
Net Debt to EBITDA
 0.36 1.18 0.34 8.91 0.53
Profitability Margins
Gross Profit Margin
-9099.11%-698.49%-1751.59%61.75%0.00%
EBIT Margin
-64902.56%-7256.41%-2485.33%-305.22%0.00%
EBITDA Margin
-58006.60%-6479.74%-2385.64%-114.82%0.00%
Operating Profit Margin
-64902.56%-7256.41%-2475.88%-6563.83%0.00%
Pretax Profit Margin
198352.64%-5851.41%-2351.51%-352.92%0.00%
Net Profit Margin
199197.33%-5851.41%-2351.51%-352.92%0.00%
Continuous Operations Profit Margin
199197.33%-5851.41%-2351.51%-352.92%0.00%
Net Income Per EBT
100.43%100.00%100.00%100.00%99.99%
EBT Per EBIT
-305.62%80.64%94.98%5.38%104.28%
Return on Assets (ROA)
348.76%-43.61%-111.16%-6.59%-52.22%
Return on Equity (ROE)
-64.89%11.11%55.21%18.90%366.94%
Return on Capital Employed (ROCE)
-439.97%19.16%86.87%1467.59%-126.04%
Return on Invested Capital (ROIC)
-425.76%19.48%94.29%-1706.05%-107.69%
Return on Tangible Assets
389.03%-46.41%-115.91%-6.72%-52.61%
Earnings Yield
43.71%-7.54%-318.37%-20.84%-97.27%
Efficiency Ratios
Receivables Turnover
 423.42 1.14K 0.84 1.63 0.00
Payables Turnover
 0.37 0.25 5.91 0.06 0.56
Inventory Turnover
 9.26 2.76 64.49 0.02 0.20
Fixed Asset Turnover
 <0.01 0.04 0.33 0.24 0.00
Asset Turnover
 <0.01 <0.01 0.05 0.02 0.00
Working Capital Turnover Ratio
 >-0.01 >-0.01 -0.05 0.07 0.00
Cash Conversion Cycle
 -937.41 -1.31K 377.44 11.14K 1.17K
Days of Sales Outstanding
 0.86 0.32 433.58 224.14 0.00
Days of Inventory Outstanding
 39.42 132.06 5.66 16.94K 1.83K
Days of Payables Outstanding
 977.69 1.45K 61.80 6.02K 657.62
Operating Cycle
 40.28 132.39 439.24 17.17K 1.83K
Cash Flow Ratios
Operating Cash Flow Per Share
 -0.21 -0.15 -0.23 -0.59 -1.53
Free Cash Flow Per Share
 -0.21 -0.15 -0.23 -0.59 -1.63
CapEx Per Share
 <0.01 <0.01 <0.01 <0.01 0.10
Free Cash Flow to Operating Cash Flow
 1.00 1.00 1.01 1.01 1.06
Dividend Paid and CapEx Coverage Ratio
 -424.17K -5.93K -177.20 -79.32 -16.02
Capital Expenditure Coverage Ratio
 -424.17K -5.93K -177.20 -79.32 -16.02
Operating Cash Flow Coverage Ratio
 -124.99 -17.94 -3.22 -2.18 -4.77
Operating Cash Flow to Sales Ratio
 -615.20 -55.80 -7.51 -18.54 0.00
Free Cash Flow Yield
-13.17%-7.19%-102.24%-110.87%-71.27%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 2.31 -13.14 -0.31 -4.80 -1.03
Price-to-Sales (P/S) Ratio
 4.67K 775.86 7.39 16.93 0.00
Price-to-Book (P/B) Ratio
 -2.41 -1.47 -0.17 -0.91 -3.77
Price-to-Free Cash Flow (P/FCF) Ratio
 -7.59 -13.90 -0.98 -0.90 -1.40
Price-to-Operating Cash Flow Ratio
 -7.41 -13.90 -0.98 -0.91 -1.49
Price-to-Earnings Growth (PEG) Ratio
 <0.01 0.17 >-0.01 0.05 0.02
Price-to-Fair Value
 -2.41 -1.47 -0.17 -0.91 -3.77
Enterprise Value Multiple
 -7.69 -10.79 0.03 -5.84 -0.53
Enterprise Value
 1.89B 2.39B -27.83M 263.36M 1.27B
EV to EBITDA
 -7.69 -10.79 0.03 -5.84 -0.53
EV to Sales
 4.46K 699.45 -0.72 6.71 0.00
EV to Free Cash Flow
 -7.25 -12.53 0.10 -0.36 -0.71
EV to Operating Cash Flow
 -7.25 -12.53 0.10 -0.36 -0.75
Tangible Book Value Per Share
 -0.65 -1.45 -1.33 -0.62 -0.64
Shareholders’ Equity Per Share
 -0.63 -1.43 -1.31 -0.59 -0.61
Tax and Other Ratios
Effective Tax Rate
 0.00 0.00 0.00 0.00 <0.01
Revenue Per Share
 <0.01 <0.01 0.03 0.03 0.00
Net Income Per Share
 0.67 -0.16 -0.72 -0.11 -2.22
Tax Burden
 1.00 1.00 1.00 1.00 1.00
Interest Burden
 -3.06 0.81 0.95 1.16 1.02
Research & Development to Revenue
 427.18 45.54 4.77 16.56 0.00
SG&A to Revenue
 152.11 19.09 1.04 1.34 0.00
Stock-Based Compensation to Revenue
 16.02 1.96 0.42 1.36 0.00
Income Quality
 -0.31 0.93 0.32 5.25 0.69
Currency in CNY